Related Experiment Video
Updated: May 19, 2026
09:52
Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
Published on: January 25, 2015
Periocular Pigmentation After Gemcitabine Monotherapy for Bladder Cancer: A Rare Case Report
Li Juan1,2, Chen Weiping1
1Macau University of Science and Technology Macau China.
Clinical Case Reports
|May 18, 2026
Summary
Gemcitabine therapy for advanced bladder cancer can cause temporary periorbital hyperpigmentation, a rare side effect. This skin discoloration around the eyes resolved after discontinuing chemotherapy, emphasizing the need for vigilant monitoring.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Advanced bladder cancer treatment often involves combination chemotherapy.
- Gemcitabine, cisplatin, and treliprimab are used in chemotherapy regimens.
- Adverse skin reactions can occur during cancer treatment.
Purpose of the Study:
- To report a rare case of periorbital hyperpigmentation associated with gemcitabine chemotherapy.
- To highlight the importance of recognizing and managing gemcitabine-induced skin side effects.
- To emphasize the need for vigilant patient monitoring during chemotherapy.
Main Methods:
- A case study of a patient with advanced bladder cancer undergoing chemotherapy.
- Clinical observation of periorbital hyperpigmentation onset and resolution.
- Review of patient's medical history and laboratory results.
Main Results:
- The patient developed severe periorbital hyperpigmentation shortly after gemcitabine infusion.
- Laboratory tests and dermatological examination revealed no other abnormalities.
- The hyperpigmentation resolved within two days of discontinuing chemotherapy.
Conclusions:
- Periorbital hyperpigmentation is a potential, albeit rare, adverse reaction to gemcitabine.
- Early recognition and discontinuation of the drug can lead to rapid improvement.
- Close dermatological monitoring is crucial for patients receiving gemcitabine.
